Senti Biosciences, Inc.

Senti Biosciences, Inc. Stock Forecast & Price Prediction

Live Senti Biosciences, Inc. Stock (SNTI) Price
$3.1

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$3.1

P/E Ratio

-0.17

Volume Traded Today

$10,610

Dividend

Dividends not available for SNTI

52 Week High/low

8.48/1.52

Senti Biosciences, Inc. Market Cap

$12.4M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $SNTI ๐Ÿ›‘

Before you buy SNTI you'll want to see this list of ten stocks that have huge potential. Want to see if SNTI made the cut? Enter your email below

SNTI Summary

From what 0 stock analysts predict, the share price for Senti Biosciences, Inc. (SNTI) might decrease by 100% in the next year. This is based on a 12-month average estimation for SNTI. Price targets go from $ to $. The majority of stock analysts believe SNTI is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

SNTI Analyst Ratings

About 0 Wall Street analysts have assigned SNTI 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Senti Biosciences, Inc. to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on SNTI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

SNTI stock forecast by analyst

These are the latest 20 analyst ratings of SNTI.

Analyst/Firm

Rating

Price Target

Change

Date

Geulah Livshits
Chardan Capital

Buy

$6

Reiterates

Aug 15, 2023
Geulah Livshits
Chardan Capital

Buy

$6

Maintains

May 11, 2023
Michael Ulz
Morgan Stanley

Equal-Weight

$2

Maintains

Mar 24, 2023
Geulah Livshits
Chardan Capital

Buy

$7

Maintains

Mar 23, 2023
Geulah Livshits
Chardan Capital

Buy

$8

Maintains

Jan 30, 2023
Michael Ulz
Morgan Stanley

Equal-Weight

$3

Maintains

Jan 27, 2023
Brian Cheng
JP Morgan

Neutral


Initiates

Dec 16, 2022
Michael Ulz
Morgan Stanley

Equal-Weight

$7.5

Initiates

Oct 7, 2022
Greg Harrison
B of A Securities

Buy

$7

Initiates

Sep 29, 2022
Geulah Livshits
Chardan Capital

Buy

$12

Initiates

Sep 23, 2022

SNTI Company Information

  • Company Type: Preclinical biotechnology company
  • Focus: Development of next-generation cell and gene therapies
  • Technology: Engineered gene circuit platform technologies
  • Lead Product Candidates:
    • SENTI-202: Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy targeting cancer cells while sparing healthy bone marrow
    • SENTI-301A: Targeting hepatocellular carcinoma
    • SENTI-401: Logic Gated off-the-shelf CAR-NK cell therapy for colorectal cancer (CRC)
  • Research Platform: Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform for identifying tumor-associated antigens
  • Strategic Collaboration: Partnership with Celest Therapeutics for clinical development of SENTI-301A
  • Incorporation: Founded in 2016, headquartered in South San Francisco, California
SNTI
Senti Biosciences, Inc. (SNTI)

When did it IPO

2021

Staff Count

48

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Dr. Timothy K. Lu M.D., Ph.D.

Market Cap

$12.4M

Senti Biosciences, Inc. (SNTI) Financial Data

In 2023, SNTI generated $2.0M in revenue, which was a decrease of -39.81% from the previous year. This can be seen as a signal that SNTI's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$394,000

Revenue From 2021

$2.3M

481.47 %
From Previous Year

Revenue From 2022

$3.3M

43.43 %
From Previous Year

Revenue From 2023

$2.0M

-39.81 %
From Previous Year
  • Revenue TTM $338,000
  • Operating Margin TTM -18,017.5%
  • Gross profit TTM $0
  • Return on assets TTM -33.0%
  • Return on equity TTM -111.1%
  • Profit Margin 0.0%
  • Book Value Per Share 9.66%
  • Market capitalisation $12.4M
  • Revenue for 2021 $2.3M
  • Revenue for 2022 $3.3M
  • Revenue for 2023 $2.0M
  • EPS this year (TTM) $-17.54

Senti Biosciences, Inc. (SNTI) Latest News

No news data available.

...

SNTI Frequently asked questions

The highest forecasted price for SNTI is $ from Brian Cheng at JP Morgan.

The lowest forecasted price for SNTI is $ from Brian Cheng from JP Morgan

The SNTI analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.